Sort   by:  
 Page size 
UnknownPhase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Not available
S-EPMC4451172 | biostudies-literature
UnknownMulticenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Not available
S-EPMC6209089 | biostudies-literature
UnknownAntimicrobial exposure is associated with decreased survival in triple-negative breast cancer.
Not available
S-EPMC10097670 | biostudies-literature
UnknownOpen-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Not available
S-EPMC6567845 | biostudies-literature
UnknownPeri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.
Not available
S-EPMC12283416 | biostudies-literature
TranscriptomicsTranscriptomes of triple negative breast cancer enriched breast cancer cohort
Breast cancers enriched for the triple negative breast cancer phenotype with extensive clinico-pathological features were profiled to establish their comprehensive transcriptional profiles
ORGANISM(S): Homo sapiens 
2016-11-21 | E-MTAB-5270 | biostudies-arrayexpress
UnknownAdjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.
Not available
S-EPMC9126186 | biostudies-literature
UnknownOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Not available
S-EPMC10207856 | biostudies-literature
Sort   by:  
 Page size